Published content in this website is for information purposes and is intended for healthcare professionals only.
Medical Education
EDUCALS, your online learning network
The EDUCALS network, tailored for neurology specialists and multidisciplinary teams, aims to be an essential resource for finding up-to-date nowledge on ALS.
We invite you to join us on this journey towards accuracy in ALS diagnosis and improved patient care.
NEW MODULE: ALS DISEASE OVERVIEW NOW AVAILABLE!
ALS Trial Design
Learn strategies to balance endpoints’ and patients’ selection and how to better engage with pALS.
ALS Diagnosis and Referral
Enhance diagnostic efficiency and minimise referral delays to improve patient and medical journeys.
ALS Disease Overview
Gain in-depth knowledge on ALS disease covering classification, epidemiology, risk factors, causes, prognosis and key pathophysiological mechanisms.
People living with ALS and their caregivers
Having Amyotrophic Lateral Sclerosis (ALS) can feel like your energy is slowly burning out. Unfortunately, this condition can be overlooked, which significantly delays diagnosis and causes serious consequences. At Ferrer we make a positive impact in society, and in order to help raise awareness of ALS, we created the Phantasticals campaign as undeniable proof of how we stand with people who live with this severe and debilitating condition. Join us in reminding everyone that while people with ALS might be rare, they’re still there. #WeBelieveInPhantasticals
Check out the ALS infographic to download and share with your patients.
Clinical Trials & Publications
Learn about the ADORE Study protocol design and results: an international, Phase 3, Randomized, Placebo-Controlled trial with Daily Oral Edaravone (FNP122) in people living with ALS
The publications contained in this section are subject to congress copyright permissions.
Consult the ADOREXT study protocol design: an international, Phase 3 Open-Label Extension Study to Investigate the Long-term Safety of Daily Oral Edaravone (FNP-122) in ALS.
The publications contained in this section are subject to congress copyright permissions.
Top-line results from Phase III ADORE study in ALS. Link to Ferrer official press release (10/01/2024)
